Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?

The treatment strategy for metastatic renal cell carcinoma (mRCC) has evolved with the emergence of anti-angiogenic drugs, in particular tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs). Both treatment options...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: R. A. Gafanov, A. G. Dzidzaria, I. B. Kravtsov, S. V. Fastovets
Fformat: Artigo
Iaith:Russo
Cyhoeddwyd: ABV-press 2020-09-01
Cyfres:Onkourologiâ
Pynciau:
angiogenesis
combination
immune checkpoint inhibitor
immunotherapy
renal cell carcinoma
tyrosine kinase inhibitor
Mynediad Ar-lein:https://oncourology.abvpress.ru/oncur/article/view/1360
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg